THE INCIDIENCE OF CHOLANGIOCARCINOMA AMONG PRIMARY SCLEROSING **CHOLANGITIS PATIENTS IS LOWER THAN PREVIOUSLY REPORTED**

Background

Primary sclerosing cholangitis (PSC) is a chronic inflammatory disease involving the bile ducts with an increased risk of cancer

Baylor

Collegeof

Medicine

• The relative risk (RR) of CCA in PSC has been reported as high as 1,560

Objectives

- To assess the utility of current screening practice in PSC patients for CCA
- To estimate the relative risk of CCA in PSC patients

Data & Methods

Source of the data: Electronic medical records of patients at Baylor St. Luke's Medical Center from 1998 to 2021

Participants: Screened 178 patients with diagnosis of PSC, 109 patient met inclusion criteria

Exclusion criteria:

- <1 year of follow up</p>
- Established care with Baylor post transplant


Variables:

- Sociodemographic variables
 - Age, gender, race
- Date of PSC diagnosis
- Date of CCA diagnosis
- Duration of follow up
- **Comorbid conditions**
 - Inflammatory bowel disease (IBD)
 - Diabetes mellitus (DM)
 - Cirrhosis
- Social history
 - Alcohol use
 - Tobacco use
- Highest lifetime carbohydrate antigen (CA) 19-9 levels
- Date of death and cause of death

Statistical analysis: A person-years analysis was conducted to compare the incidence rates of CCA in our sample to the general population. Cancer data on the general population from 1998 to 2018 was collected from the Surveillance, Epidemiology, and End Results (SEER) Program. Survival analysis with logrank test was used to assess for possible risk factors for the development of CCA.

Ronan Allencherril, MD¹, Rollin George², Susan Hilsenbeck³, PhD, Prasun Jalal, MD² ¹ Department of Internal Medicine, ² Division of Gastroenterology, ³ Dan L Duncan Comprehensive Cancer Center Baylor College of Medicine, Houston, TX

year of



Results				
	CSUILS			
	Table 2: Characteristics	of PSC coho		
	Variable			
SC patients excluded	Age (median [IQR])			
= 69				
less than 1 year of	Age at PSC diagnosis (median [IQR])			
ow-up				
ed with CCA within 1				
follow-up	Sex (%)			
er transplant prior to are with Baylor	Race (%)	Fe		
are with buyion				
		(
	IBD (%)			
		Unk		
	Cirrhosis (%)			
	Diabetes mellitus (%)			
	Alcohol use (%)	1		
n = 1 = 0 vector		Previous bu		
p 4.9 years		Curren		
intervals	Tobacco use (%)			
		Previous bu Curren		
(95% confidence		Curren		

- lower than previously reported
- Routine surveillance failed to detect CCA
- help diagnose CCA or improve mortality

ort with and without CCA

	No CCA	CCA
n	107	2
	48.00 [33.00, 64.50]	55.00 [51.50, 58.50]
	10.00 [55.00, 01.50]	55.00 [51.50, 50.50]
	37.00 [24.00, 54.50]	41.50 [34.75, 48.25]
Male	64 (59.8)	1 (50.0)
Female	43 (40.2)	1 (50.0)
White	72 (67.3)	1 (50.0)
Black	25 (23.4)	1 (50.0)
Other	10 (9.3)	0 (0.0)
No	41 (38.3)	1 (50.0)
Yes	65 (60.7)	1 (50.0)
Unknown	1 (0.9)	0 (0.0)
No	35 (33.3)	2 (100.0)
Yes	70 (66.7)	0 (0.0)
No	94 (87.9)	2 (100.0)
Yes	13 (12.1)	0 (0.0)
Never	57 (53.3)	2 (100.0)
ious but quit	33 (30.8)	0 (0.0)
Current user	17 (15.9)	0 (0.0)
Never	91 (85.0)	2 (100.0)
ious but quit	12 (11.2)	0 (0.0)
Current user	4 (3.7)	0 (0.0)

Conclusions

Risk of CCA among PSC patient is higher than general population, but

CCA patients passed away within 1 year of cancer diagnosis

Current surveillance practice with imaging and CA 19-9 levels may not